1.
Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и соавт. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин. Микробиол. Атимикроб. Химиотер. 2006; 8:54-86.
2.
Shefet D., Robenshtok E., Paul M., Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005; 165:1992-2000.
3.
Robenshtok E., Shefet D., Gafter-Gvili A., et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2008; (1):CD004418.
4.
Mills G.D., Oehley M.R., Arrol B. Effectiveness of betalactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005; 330:456.
5.
Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159:2562-72.
6.
Brown R.B., Iannini P., Gross P., Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claimsmade database. Chest. 2003; 123:1503-11.
7.
Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003; 36:389-95.
8.
Metersky M.L., Ma A., Houck P.M., Bratzler D.W. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007; 131:466-73.
9.
Синопальников А.И. Новые горизонты применения макролидов при инфекциях дыхательных путей. Российские медицинские вести. 2004; 2:23-29.
10.
Amsden G.W. Anti-inflammatory effects of macrolides- -an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005; 55:10-21.
11.
Sànchez F., Mensa J., Martнnez J.A., et al. Is azithromycin the first-choice macrolide for treatment of communityacquired pneumonia? Clin Infect Dis. 2003; 36:1239-45.
12.
Tamm M., Todisco T., Feldman C., et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect. 2007; 13:162-71.
13.
Рачина С.А., Фокин А.А., Ишмухаметов А.А., Денисова М.Н. Анализ амбулаторного потребления антимикробных препаратов для системного применения в различных регионах РФ. Клин. микробиол. антимикроб. химиотер. 2008; 10:59-69.